当前位置:
X-MOL 学术
›
Cancer Cell
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Dual Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancer: Just a Gambit or Real CheckMate?
Cancer Cell ( IF 48.8 ) Pub Date : 2020-10-12 , DOI: 10.1016/j.ccell.2020.09.009 Brooke E. Wilson , Aaron R. Hansen
中文翻译:
转移性去势抵抗性前列腺癌的双重检查点封锁:只是一个良心还是真正的CheckMate?
更新日期:2020-10-13
Cancer Cell ( IF 48.8 ) Pub Date : 2020-10-12 , DOI: 10.1016/j.ccell.2020.09.009 Brooke E. Wilson , Aaron R. Hansen
In this issue of Cancer Cell, Sharma et al. report that ipilimumab and nivolumab combination achieved impressive response rates in patients with metastatic castration-resistant prostate cancer (mCRPC). But this regimen produced high rates of toxicity, treatment-related discontinuation, and death. Tolerability needs improvement for this combination to benefit more men with mCRPC.
中文翻译:
转移性去势抵抗性前列腺癌的双重检查点封锁:只是一个良心还是真正的CheckMate?
在本期《癌细胞》中,Sharma等人。报告指出,ipilimumab和nivolumab联合使用可治疗转移性去势抵抗性前列腺癌(mCRPC)患者。但是这种方案产生高毒性,与治疗相关的停药和死亡。这种组合的耐受性需要提高,以使更多的mCRPC男性受益。